In last trading session, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) saw 1.01 million shares changing hands with its beta currently measuring 0.71. Company’s recent per share price level of $16.08 trading at -$0.16 or -0.99% at ring of the bell on the day assigns it a market valuation of $1.10B. That closing price of PHAT’s stock is at a discount of -22.57% from its 52-week high price of $19.71 and is indicating a premium of 62.25% from its 52-week low price of $6.07. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.85 million shares which gives us an average trading volume of 956.76K if we extend that period to 3-months.

For Phathom Pharmaceuticals Inc (PHAT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 10 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information

Upright in the red during last session for losing -0.99%, in the last five days PHAT remained trading in the green while hitting it’s week-highest on Friday, 10/18/24 when the stock touched $16.08 price level, adding 9.05% to its value on the day. Phathom Pharmaceuticals Inc’s shares saw a change of 76.12% in year-to-date performance and have moved 6.56% in past 5-day. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) showed a performance of -14.10% in past 30-days. Number of shares sold short was 17.22 million shares which calculate 15.37 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 27 to the stock, which implies a rise of 40.44% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would jump 25.37% in reaching the projected high whereas dropping to the targeted low would mean a gain of 25.37% for stock’s current value.

Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts

Statistics highlight that Phathom Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 79.26% of value to its shares in past 6 months, showing an annual growth rate of -138.74% while that of industry is 17.20. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -137.06% during past 5 years.

Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders

Insiders are in possession of 8.83% of company’s total shares while institution are holding 96.96 percent of that, with stock having share float percentage of 106.36%. Investors also watch the number of corporate investors in a company very closely, which is 96.96% institutions for Phathom Pharmaceuticals Inc that are currently holding shares of the company. FRAZIER LIFE SCIENCES MANAGEMENT, L.P. is the top institutional holder at PHAT for having 10.11 million shares of worth $104.13 million. And as of 2024-06-30, it was holding 17.3189 of the company’s outstanding shares.

The second largest institutional holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD, which was holding about 7.46 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.788 of outstanding shares, having a total worth of $76.89 million.